Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Henry Khederian

ProKidney (PROK) Shares Skyrocket On Promising Kidney Disease Drug Trial Results

Genetic,Research,And,Biotech,Science,Concept.,Human,Biology,And,Pharmaceutical

ProKidney Ord Shs Class A (NASDAQ:PROK) shares are trading sharply higher Wednesday morning, following a marked surge on Tuesday driven by positive clinical trial data for its chronic kidney disease (CKD) treatment.

The company’s shares are gaining again Wednesday as investors continue to cheer statistically significant and clinically meaningful results from its Phase 2 REGEN-007 trial for rilparencel.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.